Annual report
2112.TEDINET S100YJQ7
Period2025-04-01 → 2026-03-31
Filed2026-06-25
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥33.0bn | 2025-04-01 → 2026-03-31 | Cons. | Net sales |
| Revenue | ¥32.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥31.6bn | 2023-04-01 → 2024-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥27.9bn | 2022-04-01 → 2023-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥25.1bn | 2021-04-01 → 2022-03-31v | Cons. | Net sales (5-year summary) |
| Operating income | ¥3.0bn | 2025-04-01 → 2026-03-31 | Cons. | Operating income |
| Operating income | ¥2.9bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Ordinary income | ¥3.3bn | 2025-04-01 → 2026-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥3.1bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥2.1bn | 2023-04-01 → 2024-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥731m | 2022-04-01 → 2023-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥906m | 2021-04-01 → 2022-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥3.9bn | 2025-04-01 → 2026-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥3.1bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.8bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.5bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥498m | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥609m | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥2.8bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss |
| Net income | ¥2.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Total assets | ¥31.8bn | at 2026-03-31 | Cons. | Assets |
| Total assets | ¥29.4bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥27.5bn | at 2024-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥25.9bn | at 2023-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥26.1bn | at 2022-03-31v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥11.2bn | at 2026-03-31 | Cons. | Liabilities |
| Total liabilities | ¥12.8bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥20.6bn | at 2026-03-31 | Cons. | Net assets |
| Net assets / equity | ¥16.6bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥13.7bn | at 2024-03-31v | Cons. | Net assets |
| Net assets / equity | ¥11.0bn | at 2023-03-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥10.4bn | at 2022-03-31v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.9bn | at 2026-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.3bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.9bn | at 2026-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.3bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.3bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.2bn | at 2023-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥3.5bn | at 2022-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥2.7bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥3.7bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.1bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥447m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.1bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥1.1bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥520m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥227m | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥374m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥711m | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥1.9bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥2.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.8bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.4bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.7bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥100.58 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥77.91 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥53.95 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥18.28 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥22.43 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥748.7 | at 2026-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥605.5 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥500.79 | at 2024-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥403.93 | at 2023-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥381.21 | at 2022-03-31v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 64.8% | at 2026-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.5% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 49.8% | at 2024-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.6% | at 2023-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.7% | at 2022-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 14.9% | 2025-04-01 → 2026-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 14.1% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 11.9% | 2023-04-01 → 2024-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.7% | 2022-04-01 → 2023-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.0% | 2021-04-01 → 2022-03-31v | Cons. | Rate of return on equity (5-year summary) |
| Employees | 83 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 82 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 76 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 77 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 82 | at 2022-03-31v | Cons. | Number of employees |
| Revenue | ¥21.9bn | 2025-04-01 → 2026-03-31 | Standalone | Net sales |
| Revenue | ¥22.2bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥21.2bn | 2023-04-01 → 2024-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥19.3bn | 2022-04-01 → 2023-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥18.0bn | 2021-04-01 → 2022-03-31v | Standalone | Net sales (5-year summary) |
| Operating income | ¥2.7bn | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | ¥2.5bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | ¥2.8bn | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥2.6bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.7bn | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥315m | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥595m | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥3.4bn | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥2.7bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | ¥2.4bn | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | ¥1.8bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥1.2bn | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥205m | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥395m | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥28.9bn | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥26.6bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥24.8bn | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥23.7bn | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥24.4bn | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥10.9bn | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥11.8bn | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥18.0bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥14.7bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥12.2bn | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥9.9bn | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥9.5bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.2bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.3bn | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥86.04 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥66.86 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥45.17 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥7.52 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥14.55 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥20 | 2025-04-01 → 2026-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥15 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥9 | 2023-04-01 → 2024-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥5 | 2022-04-01 → 2023-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥5 | 2021-04-01 → 2022-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥654.91 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥535.96 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥444.67 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥361.28 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥348.28 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 62.4% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 55.4% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 49.0% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.7% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.9% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 14.5% | 2025-04-01 → 2026-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 13.6% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 11.2% | 2023-04-01 → 2024-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.1% | 2022-04-01 → 2023-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.2% | 2021-04-01 → 2022-03-31v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 35,000,000 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 35,000,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 35,000,000 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 35,000,000 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 35,000,000 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 44 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 43 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 43 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 44 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 45 | at 2022-03-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 73
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | capex | 2025-04-01 → 2026-03-31 | ¥0 |
| Otherother segments | depreciation | 2025-04-01 → 2026-03-31 | ¥11m |
| Otherother segments | employees | at 2026-03-31 | 1 pure |
| Otherother segments | revenue | 2025-04-01 → 2026-03-31 | ¥139m |
| Otherother segments | revenue external | 2025-04-01 → 2026-03-31 | ¥123m |
| Otherother segments | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥16m |
| Otherother segments | segment assets | at 2026-03-31 | ¥1.0bn |
| Otherother segments | segment profit | 2025-04-01 → 2026-03-31 | ¥77m |
| Reconciling Itemsreconciling | capex | 2025-04-01 → 2026-03-31 | ¥68m |
| Reconciling Itemsreconciling | depreciation | 2025-04-01 → 2026-03-31 | ¥54m |
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2026-03-31 | −¥129m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2026-03-31 | −¥129m |
| Reconciling Itemsreconciling | segment assets | at 2026-03-31 | ¥15.5bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2026-03-31 | −¥1.5bn |
| Biotechnologyreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥60m |
| Biotechnologyreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥66m |
| Biotechnologyreportable segment | employees | at 2026-03-31 | 4 pure |
| Biotechnologyreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥1.6bn |
| Biotechnologyreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥1.6bn |
| Biotechnologyreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥41m |
| Biotechnologyreportable segment | segment assets | at 2026-03-31 | ¥1.6bn |
| Biotechnologyreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥282m |
| Sugarreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥642m |
| Sugarreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥470m |
| Sugarreportable segment | employees | at 2026-03-31 | 45 pure |
| Sugarreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥31.4bn |
| Sugarreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥31.3bn |
| Sugarreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥72m |
| Sugarreportable segment | segment assets | at 2026-03-31 | ¥13.6bn |
| Sugarreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥4.2bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2025-04-01 → 2026-03-31 | ¥704m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2025-04-01 → 2026-03-31 | ¥548m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2026-03-31 | ¥33.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2026-03-31 | ¥33.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥129m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2026-03-31 | ¥16.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2026-03-31 | ¥4.6bn |
| Otherother segments | depreciation | 2024-04-01 → 2025-03-31 | ¥11m |
| Otherother segments | revenue | 2024-04-01 → 2025-03-31 | ¥135m |
| Otherother segments | revenue external | 2024-04-01 → 2025-03-31 | ¥119m |
| Otherother segments | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥16m |
| Otherother segments | segment assets | at 2025-03-31 | ¥1.0bn |
| Otherother segments | segment profit | 2024-04-01 → 2025-03-31 | ¥77m |
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥51m |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥30m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥106m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥106m |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥13.1bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥1.4bn |
| Biotechnologyreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥122m |
| Biotechnologyreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥66m |
| Biotechnologyreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥1.6bn |
| Biotechnologyreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥1.6bn |
| Biotechnologyreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥41m |
| Biotechnologyreportable segment | segment assets | at 2025-03-31 | ¥1.6bn |
| Biotechnologyreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥316m |
| Sugarreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥360m |
| Sugarreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥449m |
| Sugarreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥30.9bn |
| Sugarreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥30.8bn |
| Sugarreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥48m |
| Sugarreportable segment | segment assets | at 2025-03-31 | ¥13.7bn |
| Sugarreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥3.9bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-04-01 → 2025-03-31 | ¥482m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥527m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥32.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥32.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥106m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥16.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥4.3bn |
| Otherother segments | employees | at 2026-03-31 | 1 pure |
| Biotechnologyreportable segment | employees | at 2026-03-31 | 4 pure |
| Sugarreportable segment | employees | at 2026-03-31 | 6 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,603
| Item | Context | Value | Unit |
|---|---|---|---|
| Total amount of remuneration etc remuneration etc by category of directors and other officers | CurrentYearDuration_OutsideDirectorsAndOtherOfficersMember | 29000000 | JPY |
| Fixed remuneration remuneration by category of directors and other officers | CurrentYearDuration_OutsideDirectorsAndOtherOfficersMember | 29000000 | JPY |
| Performance based remuneration remuneration by category of directors and other officers | CurrentYearDuration_OutsideDirectorsAndOtherOfficersMember | － | JPY |
| Non monetary remuneration remuneration by category of directors and other officers | CurrentYearDuration_OutsideDirectorsAndOtherOfficersMember | － | JPY |
| Number of directors and other officers remuneration etc by category of directors and other officers | CurrentYearDuration_OutsideDirectorsAndOtherOfficersMember | 5 | |
| Number of issues shares other than those not listed investment shares held for purposes other than pure investment reporting company | CurrentYearInstant | 1 | |
| Carrying amount shares other than those not listed investment shares held for purposes other than pure investment reporting company | CurrentYearInstant | 1617000000 | JPY |
| Number of issues whose number of shares increased shares other than those not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | 1 | |
| Total acquisition cost for increased shares shares other than those not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | 1617000000 | JPY |
| Number of shares held details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | 2540000 | |
| Number of shares held details of specified investment equity securities held for purposes other than pure investment reporting company | Prior1YearInstant_Row1Member | － | |
| Book value details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | 1617000000 | JPY |
| Book value details of specified investment equity securities held for purposes other than pure investment reporting company | Prior1YearInstant_Row1Member | － | JPY |
| Number of issues shares not listed investment shares held for pure investment reporting company | Prior1YearInstant | 3 | |
| Book value equity securities not listed investment equity securities held for pure investment reporting company | Prior1YearInstant | 21000000 | JPY |
| Number of issues shares not listed investment shares held for pure investment reporting company | CurrentYearInstant | 3 | |
| Book value equity securities not listed investment equity securities held for pure investment reporting company | CurrentYearInstant | 21000000 | JPY |
| Number of issues shares other than those not listed investment shares held for pure investment reporting company | Prior1YearInstant | 2 | |
| Book value equity securities other than those not listed investment equity securities held for pure investment reporting company | Prior1YearInstant | 5727000000 | JPY |
| Number of issues shares other than those not listed investment shares held for pure investment reporting company | CurrentYearInstant | 2 | |
| Book value equity securities other than those not listed investment equity securities held for pure investment reporting company | CurrentYearInstant | 6725000000 | JPY |
| Total of dividends received equity securities not listed investment equity securities held for pure investment reporting company | CurrentYearDuration | 2000000 | JPY |
| Total of gain loss on sale equity securities not listed investment equity securities held for pure investment reporting company | CurrentYearDuration | － | JPY |
| Total of dividends received equity securities other than those not listed investment equity securities held for pure investment reporting company | CurrentYearDuration | 186000000 | JPY |
| Total of gain loss on sale equity securities other than those not listed investment equity securities held for pure investment reporting company | CurrentYearDuration | 605000000 | JPY |
| Total of valuation gain loss equity securities other than those not listed investment equity securities held for pure investment reporting company | CurrentYearDuration | 4199000000 | JPY |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E00361-000SugarReportableSegmentsMember | 45 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E00361-000SugarReportableSegmentsMember | 47 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E00361-000BiotechnologyReportableSegmentsMember | 4 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E00361-000BiotechnologyReportableSegmentsMember | 13 | |
| Number of employees | CurrentYearInstant_OtherReportableSegmentsMember | 1 | |
| Number of employees | CurrentYearInstant_CorporateSharedMember | 33 | |
| Average number of temporary workers | CurrentYearInstant_CorporateSharedMember | 1 | |
| Number of employees | CurrentYearInstant | 83 | |
| Average number of temporary workers | CurrentYearInstant | 61 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 44 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 45.1 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 17.0 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 7097000 | JPY |
| Change from previous fiscal year in average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | -0.029 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E00361-000SugarReportableSegmentsMember | 6 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E00361-000BiotechnologyReportableSegmentsMember | 4 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_OtherReportableSegmentsMember | 1 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 33 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 44 | |
| Cash and deposits | Prior1YearInstant | 3313000000 | JPY |
| Cash and deposits | CurrentYearInstant | 2892000000 | JPY |
| Notes and accounts receivable trade | Prior1YearInstant | 2061000000 | JPY |
| Notes and accounts receivable trade | CurrentYearInstant | 2102000000 | JPY |
| Merchandise and finished goods | Prior1YearInstant | 1382000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |